Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress

Therapeutic Potential of Targeting Wnt/β-Catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress

(2017) Afsane Bahrami et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer

(2017) Daniela Massihnia et al.   Journal of Hematology & Oncology

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.

(2017) Markus Hermann Moehler et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells

(2015) Jiezhong Chen et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Early detection of colorectal cancer: from conventional methods to novel biomarkers

(2015) Nasimeh Vatandoost et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models

(2014) V D'Amato et al.   BRITISH JOURNAL OF CANCER

Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients withPIK3CAmutant advanced solid tumors: preliminary efficacy and safety in patients withPIK3CAmutant ER-positive (ER+) metastatic breast cancer (MBC)

(2014) D Juric et al.   CANCER RESEARCH

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

(2014) D. Sarker et al.   CLINICAL CANCER RESEARCH

Triptolide Synergistically Enhances Antitumor Activity of Oxaliplatin in Colon Carcinoma In Vitro and In Vivo

(2014) Yisheng Liu et al.   DNA AND CELL BIOLOGY

Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma

(2013) Karen-Lise G. Spindler et al.   ACTA ONCOLOGICA

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

(2013) K. Ng et al.   CLINICAL CANCER RESEARCH

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells

(2013) Erika Martinelli et al.   INTERNATIONAL JOURNAL OF CANCER

Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

(2013) B. M. Wolpin et al.   ONCOLOGIST

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

(2012) T. Shimizu et al.   CLINICAL CANCER RESEARCH

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

(2012) G. Migliardi et al.   CLINICAL CANCER RESEARCH

The promise of mTOR inhibitors in the treatment of colorectal cancer

(2012) Dae-Dong Kim et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Targeting the PI3K signaling pathway in cancer therapy

(2012) Chandra Bartholomeusz et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells

(2012) Yu-Lin Lin et al.   PLoS One

Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

(2011) S. V. Bhagwat et al.   MOLECULAR CANCER THERAPEUTICS

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer

(2011) Jatin Roper et al.   PLoS One

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer

(2010) Sara M. Johnson et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

(2009) Krishna M. Vasudevan et al.   CANCER CELL

The antiproliferative cytostatic effects of a self-activating viridin prodrug

(2009) A. Smith et al.   MOLECULAR CANCER THERAPEUTICS

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition

(2009) A. C. Faber et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors

(2009) Fatima Haggar et al.   Clinics in Colon and Rectal Surgery

mTOR inhibitors in the treatment of cancer

(2008) Angelica Fasolo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

PTEN: a new guardian of the genome

(2008) Y Yin et al.   ONCOGENE

Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population

(2008) J Abubaker et al.   ONCOGENE

The PTEN–PI3K pathway: of feedbacks and cross-talks

(2008) A Carracedo et al.   ONCOGENE